For full session descriptions, download the 2025 program:
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
Rethinking Donor Profiles & Variability to Improve Therapeutic Outcomes
9:00 am Fireside Chat: What Does Variability Mean for Allogeneic Cell Therapy Production?
Synopsis
An interactive panel discussion from the industry leaders in the field to set the scene on the donor space. Ask your questions live to understand the expert’s thoughts on key topics including:
- Reviewing the current use of donor-derived material and the impacts of donor-based variability
- Navigating the trade-offs between efficient donor selection and consistent product quality
- Enhancing donor screening approaches to minimize variability and improve yield
9:45 am What Makes a Super Donor? Rethinking Selection Through Immune Function & Lifestyle
Synopsis
- Reimagining donor profiles by challenging assumptions about age, gender, and health
- Uncovering how lifestyle factors, including medical cannabis use, can enhance immune cell potency
- Understanding what drives individuals to become donors and how to engage them effectively
10:15 am Managing Intra-Donor Variability to Promote Consistent Cell Therapy Outputs
Synopsis
- Investigating how physiological changes within a single donor affect cell therapy quality and product consistency
- Examining molecular and metabolic factors, including immune cell state that drive intra-donor variability
- Reviewing industry approaches to donor management and screening practices aimed at minimizing variability across collection timepoints
10:45 am Morning Break & Speed Networking
Achieving Scalable Cell Therapies by Optimizing Donor Selection & Function
11:45 am Maximizing Process Yield Through Understanding Donor Variability
Synopsis
- Gaining tools to better predict process yield from donor characteristics
- Reducing manufacturing bottlenecks by smoothing production flow
- Proving product consistency to change investor sentiment about variability
12:15 pm Assessing Donor-Dependent Variability in NK Cell Expansion & Function
Synopsis
- Evaluating donor-to-donor variability to ensure consistent NK cell expansion and robust final drug product quality
- Characterizing functional differences to optimize donor selection and enhance therapeutic efficacy
- Monitoring cell health and process adaptability to guarantee reliable production across diverse donor sources
12:45 pm Lunch Break
Synopsis
Private lunch hosted by BioIVT, please inquire at info@hansonwade.com for more information.
Harmonizing Language & Technology to Strengthen Donor Selection & Product Consistency
1:45 pm Roundtable Discussion: Bridging the Gap on Donor Variability Through Clear Communication & Better Data Use
Synopsis
- Elevating awareness beyond the core community by framing donor variability in accessible, actionable terms
- Creating shared language to help align stakeholders from research to investment
- Encouraging honest reflection by revisiting data with openness and scientific curiosity
2:30 pm Overcoming Donor Variability with Computational Predictive Tools
Synopsis
- Screening donors for superior phenotypic characteristics and functional performance to identify top performers
- Feeding high-quality donor data into our computational biology platform to enhance learning
- Enabling predictive algorithms to drive the future of donor selection with increased precision and consistency
3:00 pm Afternoon Break & Networking
Leveraging Novel Discoveries & Techniques to Identify High-Performing Donors
4:00 pm Identifying the Optimal Gamma-Delta Donor Through a Strategic Screening Approach
Synopsis
- Understanding the key phenotypic traits that define an ideal Gamma-Delta T-cell donor for therapeutic use
- Learning how a structured screening strategy is used to characterize and select top-performing donors
- Exploring how donor variability impacts cell expansion and potency, informing better CAR-T development
4:30 pm Peanut Butter & Jelly – Sandwiching Stem Cells & Engineered Immune Effector Cells from Same Donor
Synopsis
- Transplanting allogeneic stem cells with an engineered graft and CAR-T cells
- Optimizing graft versus leukemia and minimizing graft versus host disease